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ABSTRACT
Purpose: To evaluate and present our initial results of a new marker (hemosiderin) for mammary sentinel lymph node identification in
an experimental model. Methods: Skins mapped like a lymphatic duct draining to the axilla in patients submitted to breast biopsy, in our
mastology service, stimulated us to try it in an animal model (female dogs). Our theory was that some blood derivate (hemosiderin) was
captured by macrophages and accessed the lymphatic ducts in direction to the axilla. Six female dogs of no defined race were studied. We
injected 0,2 ml of technetium on both superior mammary glands. After ten minutes, a 2,5 ml solution of hemolized blood (hemosiderin)
from the own animal was injected in the subareolar lymphatic plexus on the left superior mammary gland and 2,5 ml of patent
blue concomitantly and equally on the contralateral gland. Ten minutes after, incisions on both axilas were made to search, through
the lymphatic mapping and a gamma probe, the sentinel lymph nodes. Results: Seven brown sentinel lymph nodes were indentified
and also radiomarked on the left axilla. Six blue sentinel lymph nodes were identified and also radiomarked on the right axilla.
Conclusion: Preliminary studies of a potential new dye for sentinel lymph node identification are presented. It may be the change of the
current use of the blue dyes and their severe side-effects on patients submitted to sentinel lymph node biopsies.
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RESUMO
Objetivo: Avaliar e apresentar resultados preliminares de um novo marcador (hemossiderina) para a identificação de linfonodos sentinela
mamários em um modelo experimental. Métodos: Durante acompanhamento de dois casos de biópsias excisionais de tumores da mama,
no nosso serviço de mastologia, observou-se trajeto pigmentado no quadrante inferior externo daquelas mamas, sugerindo ser marcação
cutânea do ducto de drenagem linfática a partir da papila mamária em direção a axila homolateral. Levantamos a hipótese que um
derivado sanguíneo (hemossiderina) foi capturado por macrófagos obtendo acesso aos ductos linfáticos em direção à axila. Seis cadelas
sem raça definida foram estudadas. Injeção de 0,2 ml de tecnécio foi realizada em ambas as mamas superiores. Após 10 minutos, uma
solução de 2,5 ml de sangue hemolizado (hemossiderina) do próprio animal foi injetado no plexo linfático subpapilar da mama esquerda
e 2,5 ml de azul patente na mama contralateral concomitantemente e igualmente. Após mais 10 minutos, incisões axilares foram realizadas
para a procura, pela coloração e com um gama probe, dos linfonodos sentinela. Resultados: Sete linfonodos sentinela castanhos e
radiomarcados foram identificados na axila esquerda. Seis linfonodos sentinela azuis e radiomarcados foram identificados na axila
direita. Conclusão: São apresentados estudos preliminares de um potencial novo marcador para identificação do linfonodo sentinela.
Este poderá mudar o uso dos corantes vitais e de seus efeitos adversos em pacientes submetidos à biópsia do linfonodo sentinela.
Descritores: Neoplasias da Mama. Biópsia de Linfonodo Sentinela. Hemossiderina.
1Research performed at Experimental Animal Laboratory, Department of Surgery, Faculty of Medicine, Federal University of Ceara (UFC), Fortaleza,
Brazil.
Introduction
The incidence of female breast cancer has increased
0.5% since the year 2000, as reported by the International
Agency Research on Cancer. This number is greater in developing
countries due to the increase in life expectancy and change in
behavior resulting in increased exposure to risk factors.
Lymph node staging is an early event carried out during
initial patient evaluation in developed countries. Some 20% to 30%
of all cases are diagnosed quite early (in situ lesions) with negative
axillary nodes in 79% of the patients at this stage1. These values
are somewhat different in developing countries where more than
50% of the cases are diagnosed at advanced stages of the disease.
Late stages (III and IV) of breast cancer are seen in 60% of women
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who seek medical attention at the Maternidade-Escola (Federal
University of Ceara) Breast Unit. Lack of adequate surveillance
programs, the reduced number of specialists and the small number
of educational programs may account for these numbers.
Increased survival rates have been reported lately.
According to Parkin2, the overall survival rate is 91% after the
first year and 65% after five years in Europe. These values increase
to 96.8% after the first year in the United States. As primary
prevention of breast cancer is not available as yet, early detection
and treatment in the initial phase of the disease are, therefore,
the most important measures for its control3.
Available diagnostic methods include mammography,
breast ultrassonography, sentinel lymph node biopsy, and
fine-needle aspiration biopsy among others4,5. With the definition
of the sentinel lymph node as the first one which receives the
drainage of the tumoral area6, it was possible to ensure means for
the proper staging of the illness and the therapeutic approach
establishing less invasive surgery techniques.
Currently, it is admitted that the presence of metastatic
lymph nodes is the main predictor factor for prognosis of the breast
malignant neoplasia course and subsequent therapeutic program.
Lymph nodes are also valuable for staging breast cancer. In the
recent past dissection of the axillary lymph nodes was required for
this matter, resulting in a series of additional complications7.
      The principles of the sentinel lymph node were first used by
Cabanas (1973) in penis cancer. Morton et al.8 used this principles
on the identification of melanoma metastasis. He used Patent blue
dye. Giuliano et al.9 described its use for the breast cancer, also
using the vital blue dye for lymphatic mapping and then, Krag et
al.10 additionally used a radioguided model with a gamma probe
increasing the accuracy on the identification of the sentinel
lymph node.
The results of the researches on breast sentinel lymph
node are encouraging, although there are some methods which
are controversial11. One of these is the vital blue dye use for the
lymphatic mapping which may cause severe hypersensitivity
reactions on patients12. Other dyes are used, as methylene blue
which may also cause serious reactions, including skin and fat
necrosis in the site of injection13.
During the management of two patients submitted to
breast biopsy in our service, we observed their skin mapped as
the lymphatic ducts draining to axillary lymph nodes. This
observation stimulated us to try an animal model which was
described for our group. Our theory was that some blood derivate
(hemosiderin) was captured by macrophages and accessed the
lymphatic duct in direction to the axilla (Figure 1). For these
reasons, the purpose of this paper is to present our initial results
of a new marker for sentinel lymph node identification.
FIGURE 1 – Skin mapped as a lymphatic duct in direction to the axilla
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Methods
Prospective experimental surgical study approved by the
Ethic Commission in Animal Research of our university (UFC).
It took place in the experimental surgery laboratory Prof. Saul
Goldenberg in order to evaluate the use of a blood derivate
(hemosiderin) on mammary sentinel lymph node mapping in
female dogs.
Six female dogs of no defined race, with 10kg as mean
weight, were given by the zoonoses control center of Fortaleza
to be studied. These animals were part of a group programmed
for sacrifice as they may be infected by diseases which affect
men. The animals, after proper immobilization, were anesthetized
with an intramuscular application of ketamine (05-10 mg/kg)
immediately before the experiment.
For the hemoglobin use (hemosiderin precursor), 10 ml
of blood were obtained from the left internal jugular vein of the
animal to be studied. From that blood, 8 ml were stored in 2 (two)
tubes with an anticoagulant solution (EDTA), 4 ml in each tube.
These tubes were placed symmetrically in a centrifuge
for 5 (five) minutes at 3800 rpm. Then, in each tube, an interface
was observed; the upper phase is the plasma which was extracted
with a pipette. To the rest of the volume of each tube, equal volume
in mL of NaCl 0,9% was added, in order to double the final
volume. After manual homogenization, the tubes were replaced in
the centrifuge for more 5 (five) minutes at 3800 RPM. A new
interface was noted and the upper phase (a serum solution) was
once again extracted. With these steps erythrocyte concentrates
were obtained in each tube.
Once again, to the rest of the volume of each tube
(erythrocyte concentrates), equal volume of bidistilled water
was added, in order to double the final volume. Vigorous
homogenization was performed manually, causing hemolysis by
the osmolarity difference. The tubes were replaced in the
centrifuge for more 3 (three) minutes to confirm the hemolysis. If
there was no interface after this last centrifuging, the hemolysis
was confirmed. The volume of 2,5 ml of one tube (hemosiderin)
was taken to be used on the lymph node research.
The radioactive tracer (technetium 99m), the processed
blood and the patent blue (Guerbert V 2,5%) were injected in the
mammary subareolar lymphatic plexus. Following with the surgical
procedure, the two first mammary pairs (superior) of the female
dog were defined where 0,2 ml of the radioactive tracer were
injected in each mammary gland. After 10 (ten) minutes, 2,5 ml
of patent blue were injected in the right mammary gland and
2,5 ml of the processed blood were injected in the left mammary
gland, at the same time. After more 10 (ten) minutes, 5 (five) cm
incisions were made in both axillas for the sentinel lymph node
identification by its color and with the guide of a gamma-detecting
probe.
When the surgery was finished, the euthanasia of the
animal was performed injecting intravenously, all at once,
diazepam (0,5 mg/kg), acepromazine (0,1 mg/kg) and ketamine
(5-10 mg/kg) and, after 5 (five) minutes, a 20 ml solution of
potassium chloride 10%.
Preliminary results
Six experiments were performed according to the
methodology described and showed the following results. In all
animals, at least one mammary sentinel lymph node, each one
colored and radiomarked, was identified from each axilla. In the
total, 13 (thirteen) mammary sentinel lymph nodes colored and
radiomarked were identified from all axillas (Table 1).
TABLE 1 – Number of mammary sentinel lymph nodes colored and radiomarked found in each axilla by animal
Animal Right mammary gland  
(patent blue + tecnecium) 
Left mammary gland 
(hemosiderin + tecnecium) 
1 1 lymph node 1 lymph node 
2 1 lymph node 1 lymph node 
3 1 lymph node 1 lymph node 
4 1 lymph node 1 lymph node 
5 1 lymph node 1 lymph node 
6 1 lymph node 2 lymph nodes 
All the sentinel lymph nodes found in the right axillas
were radiomarked and had a blue color. All the sentinel lymph nodes
found in the left axillas were radiomarked and had a brown color
(Figure 2). We observed that both colors were different from those
of control lymph nodes (Figure 3). There were no problems or
difficulties on finding mammary sentinel lymph nodes in the
axillas of the female dogs with these techniques.
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FIGURE 3 – Sentinel lymph nodes marked with hemosiderin at left (bold arrows) and with patent
blue at right (thin arrows). NSL = Non-sentinel lymph node.
Discussion
Sleth14, while discussing, in his
work, the annual rise on the incidence of
adverse reactions to blue dyes during
sentinel lymph node biopsies, the clearly
quantifiable allergic risks and the
continuous evolution of the sentinel
lymph node study in other tumors, asked
if it was not the time to change the dye.
Nowadays, reactions to vital
dyes are being more frequently reported
due to its increased use in lymphatic
mappings and in sentinel lymph node
biopsies in patients with breast cancer
and other malignancies12,15. Cases and
meta-analysis of anaphylactic reactions
are described due to the use of blue dyes
in sentinel lymph node identification.
The incidence of anaphylactic reactions
to isosulfan blue or patent blue vary
from 0,6% to 2,7% in patients submitted
to sentinel lymph node biopsy and
must be known by the surgeon and the
anesthesiologist16.
Mertes et al.15 reported 14
clinical cases of anaphylaxis induced by
dyes during the years 2004 and 2006 in
four different allergoanesthesia french
centers. All patients suffered hypersensitive
reactions to patent blue V during sentinel
lymph node biopsy due to breast cancer.
In this study, 43% of patients suffered
life-threatening reactions (cardiovascular
collapse, tachycardia or bradycardia,
arrhythmias and severe bronchospasm)
and 64% of these patients required
prolonged continuous epinephrine
infusion and transference to an intensive
care unit. The authors recommended the
use of dermatologic tests for these
markers before surgery.
Wohrl et al .17 described a
near-fatal case of anaphylaxis due to the
patent blue V dye in sentinel lymph node
identification. A patient with melanoma
suffered cardiac arrest for 10 minutes and
required mechanic cardio-pulmonary
reanimation measures after the intradermal
injection of this dye.
The preliminary results of our
experimental work showed that the blood
derivate (hemosiderin) was capable of
being used along with the radiomarker
( t e c h n e t i u m  9 9 m )  a n d  c o l o r i n g
wonderfully the sentinel lymph node of
female dogs.
 
FIGURE 2 – Sentinel lymph node marked with hemosiderin in vivo
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The use of the blood derivate (hemosiderin) with the
radiomarker also showed equal results comparing the use of the
patent blue with the radiomarker in identifying the mammary
sentinel lymph nodes of the female dog because they were always
found in both axillas.
The hemosiderin, a blood-derived marker, theoretically
does not cause side effects as allergic reactions. Besides, it may
decrease personal and healthcare spendings, reduce the morbidity
of the procedure and the emotional suffering, along with other
indirect vantages.
Conclusion
Preliminary studies of a potential new dye for sentinel
lymph node identification are presented. It may be the change of
the current use of the blue dyes and their severe side-effects on
patients submitted to sentinel lymph node biopsies.
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